← Leaderboard
ALNY
Ticker
ALNY
Alnylam Pharmaceuticals, Inc.
PHARMACEUTICAL PREPARATIONS
Congressional Trades
3
by 2 members
Buys
0
0%
Sells
3
100%
Total Volume
$73K
midpoint
Unique Traders
2
members
Party Breakdown
Democrats1 · 33%
Republicans2 · 67%
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthALIGNEDBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
Democrat ←
Month
→ Republican
0▲1▼
Jan '24
—
—
May '25
0▲2▼
Democrats0▲1▼Net sellers
vs
Republicans0▲2▼Net sellers
Net buyingNet selling⚡ Party split
💼 Lobbying Filings
all →- 2026-04-20$430KALNYLAM PHARMACEUTICALS INC.Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing Issues relating to supply chain tariffs Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.
- 2026-04-20$60KALNYLAM PHARMACEUTICALS INC.RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; P.L. 119-21; U.S. Competitiveness
- 2026-04-20$60KALNYLAM PHARMACEUTICALS INC.Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act.
- 2026-04-17$60KALNYLAM PHARMACEUTICALS INC.Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
- 2026-04-17$50KALNYLAM PHARMACEUTICALS INC.General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.
- 2026-04-16$60KALNYLAM PHARMACEUTICALS INC.Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
- 2026-01-20$390KALNYLAM PHARMACEUTICALS INC.Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing. Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act Issues relating to supply chain tariffs
- 2026-01-20$60KALNYLAM PHARMACEUTICALS INC.Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.
- 2026-01-20$60KALNYLAM PHARMACEUTICALS INC.RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21; U.S. Competitiveness
- 2026-01-20$60KALNYLAM PHARMACEUTICALS INC.Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
Congressional Momentum
buy vs. sell pressureDISTRIBUTINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
No trades
Last 90 Days
No trades
All-Time
▼0
0 buys3 total3 sells
$0 buys · $73K sells
Cumulative Net Position (buy vol − sell vol)
-$73K
2024-013 trades plotted2025-05
Trade Activity Timeline
Congressional buys & sells by month · last 2 months w/ activity
24/01
25/05
BuysSellsOtherHigh-volume month
Who Moved First
each row = one member · sorted by earliest disclosed trade0 buyers ·2 sellers
BuySellOtherDot size ∝ trade size · top 2 most-active traders shown
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay |
|---|---|---|---|---|
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 42d |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 3d |
| 2024-01-29 | DJosh Gottheimer | SELL | $1K – $15K | 17d |